Filing Flows › Lineage Cell Therapeutics (LCTX) › Q1 2026 › vs Q4 2025
Lineage Cell Therapeutics (LCTX) Q1 2026 vs Q4 2025 (quarter over quarter)
Lineage Cell Therapeutics's revenue fell $4.9M (-74%) from $6.6M in Q4 2025 to $1.7M in Q1 2026.
Lineage Cell Therapeutics, Q1 2026: revenue $1.7M (+15% year over year), operating margin -440.2%, net loss $4.8M, operating cash flow −$8.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7M | $6.6M | −$4.9M | -74% |
| Other income, net | $2.8M | $7.4M | −$4.6M | -62% |
| Net loss | $4.8M | −$892K | $5.7M | — |
| Costs & expenses | $9.3M | $14.0M | −$4.7M | -34% |
| Operating costs | $9.3M | $13.2M | −$3.8M | -29% |
| Research & development | $4.2M | $8.2M | −$4.0M | -49% |
| General & admin | $5.1M | $4.9M | $232K | +5% |
| Operating cash sources | $9.4M | $6.2M | $3.3M | +53% |
| Depreciation & amortization | $188K | $186K | $2K | +1% |
| Share-based compensation | $1.2M | $1.1M | $74K | +7% |
| Cash used in operations | $8.1M | $4.9M | $3.2M | +66% |
| Net loss absorbed | $4.8M | −$892K | $5.7M | — |
| Working capital & other | $4.6M | $7.1M | −$2.4M | -34% |
Questions
How much did Lineage Cell Therapeutics's revenue grow quarter over quarter in Q1 2026?
Lineage Cell Therapeutics's revenue fell $4.9M (-74%) from $6.6M in Q4 2025 to $1.7M in Q1 2026.